Portfolio → NEXT Life Sciences
NEXT Life Sciences
NEXT Life Sciences is developing Plan A, a long-acting, non-hormonal, fully reversible male contraceptive advancing through clinical development. The platform is expanding into additional reproductive-health programs, including endometriosis, targeting some of the largest and most underserved markets in healthcare.
Visit NEXT Life SciencesMore from the portfolio
Bloomlife
Bloomlife is modernizing maternal care with a remote monitoring platform for high-risk pregnancies. It offers reimbursable monitoring for conditions such as hypertension and diabetes and is preparing to launch the first FDA-cleared at-home fetal non-stress test, built on proprietary biosignal technology for Medicaid, rural, and underserved populations.
CRISPR QC
CRISPR QC brings real-time quality control into gene-editing workflows, turning a slow, opaque 'black box' process into one that is measurable, predictable, and dramatically faster. Its SaaS platform and chip make CRISPR safe and scalable for therapeutic applications.
Raydiant Oximetry
Raydiant Oximetry is developing next-generation technologies to make childbirth safer for mothers and babies. Its flagship Lumerah is the world's first non-invasive fetal pulse oximeter, directly measuring fetal oxygen to reduce unnecessary emergency C-sections, with Daisy targeting postpartum hemorrhage. Built by pioneers of pulse oximetry, with a 2025 GE Healthcare partnership.